The Clinical Cohort Study of Reproductive Health
1 other identifier
observational
3,000
0 countries
N/A
Brief Summary
The study will conduct a multicenter prospective clinical cohort study to collect comprehensive health information and essential specimens from pre-pregnancy to postpartum offspring development. We will combine the reproductive medicine with the big data technologies and cloud computing to explore the key factors which will induce the occurrence the reproductive disorders and effect the health of women and offspring. Based on the discovery of the cohort study, we will construct a prediction model for improvement of ART,optimizing the effectiveness and safety of ART.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2022
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 9, 2021
CompletedFirst Posted
Study publicly available on registry
December 20, 2021
CompletedStudy Start
First participant enrolled
January 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2024
CompletedDecember 20, 2021
December 1, 2021
2.4 years
December 9, 2021
December 17, 2021
Conditions
Outcome Measures
Primary Outcomes (5)
live birth rate
Number of women with live births / number of women randomized to the specific group.
1 day after delivery
birth weight
Weight of newborns at delivery.
1 day after delivery
weight
the weight of offspring
Change from the date of delivery up to 2 years after delivery
height
the height of offspring
Change from the date of delivery up to 2 years after delivery
Incidence of mental diseases and metabolic dysfunction
from the date of delivery up to 2 years after delivery
Secondary Outcomes (4)
implantation rate
11-12 weeks after embryo transfer
clinical pregnancy rate
6 weeks after embryo transfer
preterm birth rate
28 gestational weeks to 37 gestational weeks
neonatal complication rate
1 day after delivery
Study Arms (2)
ART couples
Couples in reproductive age undergoing ART treatment
natural pregnancy couples
Couples who get pregnant naturally
Interventions
Participant completes baseline interview at enrollment, then completes questionnaires and provides biological samples at each scheduled study visit.
Eligibility Criteria
Study subjects will be recruited from couples seeking treatment of infertility or getting pregnant naturally and wanting to deliver their babies in the study hospitals. Men must be at least 22 years old and women must be at least 20 years to participate in the study.
You may qualify if:
- Couples undergoing treatment for infertility or getting pregnant naturally and wanting to deliver their babies in study hospitals.
- Men 22-55 years old
- Women 20 - 45 years old
You may not qualify if:
- Any individual or couple who is outside of age range .
- Any couple who don't plan to complete their pregnancy check-up or deliver their babies in study hospitals.
- Any couples had participated in other clinical studies.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 3 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Vice president
Study Record Dates
First Submitted
December 9, 2021
First Posted
December 20, 2021
Study Start
January 1, 2022
Primary Completion
June 1, 2024
Study Completion
December 1, 2024
Last Updated
December 20, 2021
Record last verified: 2021-12
Data Sharing
- IPD Sharing
- Will not share
All data relevant to the study will be generated in the article or uploaded as supplementary information. Deidentified participant data will be available from Dr. Dan Zhang (zhangdan@zju.edu.cn) on a reasonable request. Protocols and statistical analysis plans will be included as supplementary information.